Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Non-cash Items (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Non-cash Items for 5 consecutive years, with $488305.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items fell 95.4% year-over-year to $488305.0, compared with a TTM value of $488305.0 through Dec 2025, down 95.4%, and an annual FY2025 reading of $488305.0, up 183.78% over the prior year.
  • Non-cash Items was $488305.0 for Q4 2025 at Aligos Therapeutics, up from $398541.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $47.1 million in Q2 2021 and bottomed at $149960.0 in Q3 2024.
  • Average Non-cash Items over 5 years is $5.6 million, with a median of $2.7 million recorded in 2022.
  • The sharpest move saw Non-cash Items crashed 99.58% in 2022, then surged 2332.13% in 2023.
  • Year by year, Non-cash Items stood at $16.8 million in 2021, then crashed by 77.75% to $3.7 million in 2022, then skyrocketed by 62.19% to $6.0 million in 2023, then skyrocketed by 75.4% to $10.6 million in 2024, then plummeted by 95.4% to $488305.0 in 2025.
  • Business Quant data shows Non-cash Items for ALGS at $488305.0 in Q4 2025, $398541.0 in Q3 2025, and $307792.0 in Q2 2025.